Abstract
Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia
Current Pharmaceutical Design
Title: Pharmacotherapy for Smoking Cessation: Present and Future
Volume: 17 Issue: 14
Author(s): Henri-Jean Aubin, Laurent Karila and Michel Reynaud
Affiliation:
Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia
Abstract: Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Export Options
About this article
Cite this article as:
Aubin Henri-Jean, Karila Laurent and Reynaud Michel, Pharmacotherapy for Smoking Cessation: Present and Future, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150837
DOI https://dx.doi.org/10.2174/138161211796150837 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isolated Tongue Angioedema after Alteplase Infusion in Acute Ischemic
Stroke
Current Drug Safety Medicinal Plants with Multiple Effects on Cardiovascular Diseases: A Systematic Review
Current Pharmaceutical Design Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Antibodies Against Complement System in SLE and their Potential Diagnostic Utility
Current Rheumatology Reviews The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Efficacy and Safety of H1-Antihistamines: An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Antihistamine Use in Dermatologic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial
Current Enzyme Inhibition Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol
Current Vascular Pharmacology Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
Current Clinical Pharmacology Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design